1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
نویسندگان
چکیده
منابع مشابه
Population PK/PD Analysis
Pharmacokinetics and pharmacodynamics are divisions of pharmacology that study the action of the body on the drug and the action of the drug on the body, respectively. They complete dose titration studies aimed to select rational dosage regimens. The classical pharmacokinetic (PK)/pharmacodynamic (PD) studies are experimental. They are usually performed on healthy volunteers or highly selected ...
متن کاملanalysis of ruin probability for insurance companies using markov chain
در این پایان نامه نشان داده ایم که چگونه می توان مدل ریسک بیمه ای اسپیرر اندرسون را به کمک زنجیره های مارکوف تعریف کرد. سپس به کمک روش های آنالیز ماتریسی احتمال برشکستگی ، میزان مازاد در هنگام برشکستگی و میزان کسری بودجه در زمان وقوع برشکستگی را محاسبه کرده ایم. هدف ما در این پایان نامه بسیار محاسباتی و کاربردی تر از روش های است که در گذشته برای محاسبه این احتمال ارائه شده است. در ابتدا ما نشا...
15 صفحه اولAn improved approach for confirmatory phase III population pharmacokinetic analysis.
In contrast to the traditional extensive exploratory approach, the authors propose a confirmatory approach to phase III population pharmacokinetics for regulatory submissions. In their approach, they recommend a prespecified primary analysis based on phase I/II data and phase III study design. Their approach also incorporates several specific sensitivity analyses to evaluate the robustness of t...
متن کاملBTX Hydrogenation in liquid phase using nanoparticles of Cobalt/MWCNTs and data analysis using RSM method
BTX compounds (Benzene, toluene and xylenes) are the main pollutants in air and fuels. Recent environmental legislations are limited the amount of these materials specially the amount of benzene in gasoline due to its carcinogen effects on health. In this research, the BTX hydrogenation was carried out using nanoparticles of Co supported on MWCNTs (multiwall carbon nanotubes) and AC (activated ...
متن کاملPopulation pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.
Oritavancin is a lipoglycopeptide antibiotic with activity against Gram-positive bacteria. Here we describe oritavancin population pharmacokinetics and the impact of patient-specific covariates on drug exposure variability. Concentration-time data were analyzed from two phase 3 clinical trials, SOLO I and SOLO II, in which oritavancin was administered as a single 1,200-mg dose to patients with ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Open Forum Infectious Diseases
سال: 2018
ISSN: 2328-8957
DOI: 10.1093/ofid/ofy210.1172